Canbridge Pharmaceuticals (FRA:MF1) Non Operating Income: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MF1 Canbridge Pharmaceuticals Inc FRA:MF1
48 GF Score
Price €0.19
GF Value €0.04
! 6 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals Non Operating Income?

Canbridge Pharmaceuticals FRA:MF1 -1.05% 48 Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:MF1 with a GF Score™ of 48/100 and a GF Value™ of €0.04. The stock has 6 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Canbridge Pharmaceuticals's Non Operating Income for the six months ended in Dec. 2025 was €0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Canbridge Pharmaceuticals Non Operating Income Related Terms

Canbridge Pharmaceuticals Non Operating Income Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals Non Operating Income Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:MF1
48GF Score
Canbridge Pharmaceuticals Inc FRA:MF1
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €0.00 Mil mean?
Canbridge Pharmaceuticals (FRA:MF1) has a Non Operating Income of €0.00 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Canbridge Pharmaceuticals and its competitors.
Is Canbridge Pharmaceuticals' Non Operating Income too high?
Canbridge Pharmaceuticals' current Non Operating Income is €0.00 Mil. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Non Operating Income compare to VRTX and REGN?
Canbridge Pharmaceuticals' Non Operating Income of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Canbridge Pharmaceuticals and its competitors. Canbridge Pharmaceuticals's current Non Operating Income is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current Non Operating Income of €0.00 Mil. The stock's GF Value™ is €0.04, compared to a current price of €0.19 — trading 370% above its estimated fair value. The current Non Operating Income is €0.00 Mil. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of €0.19 is trading 370% above its estimated GF Value™ of €0.04.

Key valuation signals for FRA:MF1:

  • Non Operating Income: €0.00 Mil
  • GF Value™: €0.04 vs. price of €0.19 (370% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Other Exchanges 01228:Hong Kong
Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for FRA:MF1

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.04
GF Value